Published March 10, 2023
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses Dexamethasone (Ozurdex) 0.7 mg intravitreal implant.
- Indication: For the treatment of adult patients with diabetic macular edema who are pseudophakic.